Emerald Mutual Fund Advisers Trust Boosts Stake in Savara Inc. (NASDAQ:SVRA)

Emerald Mutual Fund Advisers Trust boosted its position in Savara Inc. (NASDAQ:SVRA - Free Report) by 46.4% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,014,456 shares of the company's stock after purchasing an additional 638,568 shares during the quarter. Emerald Mutual Fund Advisers Trust owned about 1.17% of Savara worth $5,580,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Altium Capital Management LLC grew its holdings in Savara by 0.3% in the 4th quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock valued at $4,848,000 after buying an additional 4,000 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Savara by 13.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock valued at $135,000 after buying an additional 5,236 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock valued at $441,000 after buying an additional 5,450 shares in the last quarter. Barclays PLC grew its holdings in Savara by 2.5% in the 4th quarter. Barclays PLC now owns 236,705 shares of the company's stock valued at $728,000 after buying an additional 5,700 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Savara by 25.3% during the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company's stock worth $92,000 after purchasing an additional 6,532 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Stock Down 8.8%

NASDAQ SVRA traded down $0.22 during trading hours on Tuesday, hitting $2.29. 684,196 shares of the company were exchanged, compared to its average volume of 1,267,138. The company has a quick ratio of 14.91, a current ratio of 14.91 and a debt-to-equity ratio of 0.20. The firm has a market cap of $395.80 million, a price-to-earnings ratio of -4.77 and a beta of 0.31. The company has a 50 day moving average of $2.47 and a two-hundred day moving average of $2.71. Savara Inc. has a 52-week low of $1.89 and a 52-week high of $5.03.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, meeting analysts' consensus estimates of ($0.12). Equities research analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Evercore ISI decreased their price objective on shares of Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a report on Wednesday, May 28th. HC Wainwright lowered Savara from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $6.00 to $2.00 in a research report on Thursday, May 29th. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price objective (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Finally, Wells Fargo & Company cut their price objective on Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $5.60.

Insider Buying and Selling

In other news, Director Richard J. Hawkins acquired 48,225 shares of the company's stock in a transaction on Friday, June 20th. The shares were bought at an average price of $2.04 per share, with a total value of $98,379.00. Following the completion of the acquisition, the director owned 115,466 shares in the company, valued at $235,550.64. This trade represents a 71.72% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.13% of the stock is owned by corporate insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.